CA3015347A1 - Formulations of antibody molecules to influenza virus - Google Patents

Formulations of antibody molecules to influenza virus Download PDF

Info

Publication number
CA3015347A1
CA3015347A1 CA3015347A CA3015347A CA3015347A1 CA 3015347 A1 CA3015347 A1 CA 3015347A1 CA 3015347 A CA3015347 A CA 3015347A CA 3015347 A CA3015347 A CA 3015347A CA 3015347 A1 CA3015347 A1 CA 3015347A1
Authority
CA
Canada
Prior art keywords
formulation
seq
antibody molecule
sequence
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3015347A
Other languages
English (en)
French (fr)
Inventor
Susan Sloan
Bi XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of CA3015347A1 publication Critical patent/CA3015347A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3015347A 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus Pending CA3015347A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299162P 2016-02-24 2016-02-24
US62/299,162 2016-02-24
PCT/US2017/019053 WO2017147248A1 (en) 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus

Publications (1)

Publication Number Publication Date
CA3015347A1 true CA3015347A1 (en) 2017-08-31

Family

ID=58264606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015347A Pending CA3015347A1 (en) 2016-02-24 2017-02-23 Formulations of antibody molecules to influenza virus

Country Status (7)

Country Link
US (3) US20170240617A1 (https=)
EP (1) EP3419663A1 (https=)
JP (2) JP7104629B2 (https=)
CN (1) CN109195629A (https=)
AU (2) AU2017222564A1 (https=)
CA (1) CA3015347A1 (https=)
WO (1) WO2017147248A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
CN119161468A (zh) 2014-07-15 2024-12-20 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
CN113480640B (zh) 2015-06-01 2024-07-30 免疫医疗有限责任公司 中和抗流感结合分子及其用途
WO2017083627A1 (en) * 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2017123685A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
CN111393512B (zh) * 2020-03-24 2021-03-02 北京中科微盾生物科技有限责任公司 一种抑制流感病毒的多肽及其在制备预防和治疗流感病毒感染药物中的应用
US20220135653A1 (en) * 2020-11-05 2022-05-05 Bravado Pharmaceuticals, LLC Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections
CN116589569B (zh) * 2023-03-06 2024-06-07 中国农业科学院兰州兽医研究所 一种抗h7n9亚型流感病毒ha蛋白的纳米抗体及其噬菌体展示文库的构建方法和应用

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IL63224A (en) 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4625015A (en) 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JP2518607B2 (ja) 1985-08-29 1996-07-24 雪印乳業株式会社 インフルエンザａ型ウイルスｈａ抗原に対するモノクロ―ナル抗体およびその作成方法
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
DE19643314A1 (de) 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
US6723359B2 (en) 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
AU2004215133B2 (en) 2003-02-27 2010-10-14 Yeda Research And Development Co. Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CN100522998C (zh) * 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
DK1692265T3 (da) 2003-11-04 2011-11-21 Univ Tulane Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
CA2879182C (en) 2004-05-25 2017-02-14 Medimmune, Inc. Influenza hemagglutinin and neuraminidase variants
EP1828232A2 (en) 2004-12-22 2007-09-05 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
EP1851238A4 (en) 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CA2637837A1 (en) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
JP2009540801A (ja) 2006-06-16 2009-11-26 ダウ・アグロサイエンス・エル・エル・シー トリインフルエンザ赤血球凝集素の新規なｄｎａ配列、ベクターおよびタンパク質
US20080241918A1 (en) 2006-08-14 2008-10-02 Ram Sasisekharan Hemagglutinin polypeptides, and reagents and methods relating thereto
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
JP4625485B2 (ja) 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
US8030029B2 (en) 2007-01-23 2011-10-04 Academia Sinica Flu vaccines and methods of use thereof
WO2008110937A2 (en) 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
JP5597128B2 (ja) 2007-05-11 2014-10-01 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５トリインフルエンザの診断および監視に有用なｈ５亜型特異的結合タンパク質
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP2716656B1 (en) 2007-06-15 2016-10-12 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof
WO2008156763A2 (en) 2007-06-15 2008-12-24 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to h5n1 influenza a virus
SG183031A1 (en) 2007-09-13 2012-08-30 Temasek Life Sciences Lab Ltd Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
WO2009035412A1 (en) 2007-09-13 2009-03-19 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
EP2217064A4 (en) 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
US8574830B2 (en) 2008-02-05 2013-11-05 Temasek Life Sciences Laboratory Limited Binding protein and epitope-blocking ELISA for the universal detection of H5-subtype influenza viruses
CA2717221C (en) 2008-03-12 2015-11-24 Xuguang Li (Sean) Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
JP5586064B2 (ja) 2008-03-28 2014-09-10 国立大学法人北海道大学 抗ｈ５亜型ａ型インフルエンザウイルスヘマグルチニンモノクローナル抗体
FI20080333A0 (fi) 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2010006144A2 (en) 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants
WO2010010467A2 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
US20100061995A1 (en) 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
GB0818356D0 (en) 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
WO2010040281A1 (zh) 2008-10-09 2010-04-15 厦门大学 H5亚型禽流感病毒血凝蛋白的人源化抗体及其用途
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
WO2010074656A1 (en) 2008-12-24 2010-07-01 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
JP5780762B2 (ja) 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
WO2010127252A2 (en) 2009-04-30 2010-11-04 Vanderbilt University Monoclonal antibodies to influenza h1n1 virus and uses thereof
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
US9278998B2 (en) 2009-07-02 2016-03-08 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US9458226B2 (en) 2009-10-09 2016-10-04 Emory University Recombinant antibodies against H1N1 influenza
WO2011068143A1 (ja) 2009-12-03 2011-06-09 独立行政法人科学技術振興機構 Ｈ５亜型インフルエンザウイルスに対する抗体およびその利用
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2011094445A1 (en) 2010-01-27 2011-08-04 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
JPWO2011093217A1 (ja) 2010-01-29 2013-06-06 富士レビオ株式会社 抗Ｐａｎｄｅｍｉｃ（Ｈ１Ｎ１）２００９抗体及びそれを用いた免疫測定方法
WO2011096302A1 (ja) 2010-02-02 2011-08-11 国立大学法人名古屋大学 薬剤耐性インフルエンザウイルス特異的抗体及びその用途
JP2011160681A (ja) 2010-02-05 2011-08-25 Japan Science & Technology Agency Ａ型インフルエンザのヘマグルチニンに対する抗体およびその利用
WO2011111966A2 (en) 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
WO2011117848A1 (en) 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
ES2687706T3 (es) 2010-06-17 2018-10-26 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la gripe
WO2012021786A2 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US8992929B2 (en) 2010-08-23 2015-03-31 Temasek Life Sciences Laboratory Limited Monoclonal antibody specific to major neutralizing epitope of influenza H5 hemagglutinin
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012040406A2 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
BR112013007946B1 (pt) 2010-10-04 2022-07-12 Massachusetts Institute Of Technology Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina
US8900585B2 (en) 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
EP2646050B1 (en) 2010-12-02 2016-09-07 mAB-Factory GmbH Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections
AU2012205663B2 (en) 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
DK2731967T3 (en) 2011-07-14 2017-01-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS
HRP20190714T1 (hr) 2011-07-18 2019-06-14 Institute For Research In Biomedicine Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
CN104114186B (zh) 2011-08-03 2017-05-03 儿童医疗中心有限公司 识别流行性感冒血凝素的受体‑结合袋状结构的广泛中和人类抗体
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
WO2013044840A1 (zh) 2011-09-30 2013-04-04 中国科学院上海巴斯德研究所 高致病性禽流感的中和分子及其制备方法
MX350282B (es) 2011-09-30 2017-09-01 Celltrion Inc Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
EP2768858B1 (en) 2011-10-18 2018-08-01 Emory University Antibodies directed against influenza
KR20130059721A (ko) 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
ES2686526T3 (es) 2011-12-05 2018-10-18 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la influenza
KR101749316B1 (ko) 2011-12-15 2017-06-21 (주) 에이프로젠 Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
WO2013114885A1 (en) 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
AU2013229488B2 (en) 2012-03-08 2017-12-07 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
HK1207970A1 (en) 2012-05-10 2016-02-19 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US8710470B2 (en) * 2012-07-12 2014-04-29 The United States Of America, As Represented By The Secretary Of The Navy Wavelength and power scalable waveguiding-based infrared laser system
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP6518597B2 (ja) 2013-02-07 2019-05-22 マサチューセッツ インスティテュート オブ テクノロジー Ｈ５インフルエンザのヒトへの適応
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
RU2682049C2 (ru) 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
PE20170261A1 (es) 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
KR102668588B1 (ko) 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2016374416A1 (en) 2015-12-15 2018-06-14 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
CN115551885A (zh) 2019-12-11 2022-12-30 威特拉公司 用于治疗和预防流感的组合物和方法

Also Published As

Publication number Publication date
US20210054053A1 (en) 2021-02-25
JP2022110149A (ja) 2022-07-28
US20200181243A1 (en) 2020-06-11
JP2019512012A (ja) 2019-05-09
JP7104629B2 (ja) 2022-07-21
AU2024202246A1 (en) 2024-06-27
AU2017222564A1 (en) 2018-09-06
US12202885B2 (en) 2025-01-21
CN109195629A (zh) 2019-01-11
US20170240617A1 (en) 2017-08-24
WO2017147248A1 (en) 2017-08-31
EP3419663A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
US12202885B2 (en) Formulations of antibody molecules to influenza virus
US12024552B2 (en) Ha binding agents
US10513553B2 (en) Compositions and methods for treating and preventing influenza
US11230593B2 (en) Compositions and methods for treating and preventing influenza
US20230257449A1 (en) Compositions and methods for treating and preventing influenza
HK40035221A (en) Novel ha binding agents
HK1208619B (en) Novel ha binding agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220222

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250522

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250915

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251117